

1 **Supplementary Figures**
2




3
4 Supplementary Figure 1: Intermediate impact of tofacitinib treatment on CD4⁺ and CD8⁺ T lymphocytes.
5 PBMC were isolated from T3^b-hIL-15 Tg mice that were undergoing tofacitinib therapy at 10 and 20 days
6 after the initiation of tofacitinib treatment and the impact of the drug on peripheral blood CD4⁺ and CD8⁺
7 T lymphocytes were assessed by flow cytometry. The modulation of these T cell subsets in three
8 individual mice that were being treated with tofacitinib is shown.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

before treatment




74-1

74-5




74-6



10 days with treatment



20 days with treatment



CD8